VELVERT联合单层与四层压力治疗静脉性腿溃疡的多中心随机开放三臂上市后研究
第60天VELVERT+VELSOFT组伤口面积缩小67.03%、完全闭合率50.0%最高,三组疼痛均改善且不良事件轻微。
要点
- VELVERT+VELSOFT组伤口面积缩小67.03%、完全闭合率50.0%,为三组最高。
- VELVERT与VELVERT+VELSOFT组实现完全微生物清除,VELFOUR组有少量残留。
- 三组疼痛评分均显著改善,不良事件少见且与器械无关。
核心结论
- 三种治疗方案均改善伤口愈合、疼痛和感染控制。
- VELVERT联合VELSOFT显示最一致的临床获益,包括更大的伤口面积缩小、最高闭合率、完全微生物清除和良好安全性。
- 研究支持VELVERT联合VELSOFT及VELVERT单用作为有效且耐受性好的压力治疗伤口护理选择。
研究设计与样本
- 多中心、随机、干预性、开放标签临床研究,在MLB Medical College, Jhansi和Nizam Institute of Medical Sciences, Hyderabad开展。
- 主要终点包括完全伤口闭合、伤口面积缩小百分比和微生物学评估;次要终点为疼痛强度、安全性和愈合所需敷料数量。
主要发现
- 第60天平均伤口面积缩小:VELVERT组57.72%(n=22),VELVERT+VELSOFT组67.03%(n=20),VELFOUR组65.79%(n=19)。
- 总体42.6%受试者实现完全伤口闭合,VELVERT+VELSOFT组最高为50.0%,VELFOUR组42.1%,VELVERT组36.4%。
- VELVERT和VELVERT+VELSOFT组实现完全微生物清除,VELFOUR组观察到少量残留微生物生长。
- 所有组疼痛评分显著改善,不良事件不频繁、轻至中度且与研究器械无关。
临床怎么用
- 对于静脉性腿溃疡患者,可考虑VELVERT联合VELSOFT单层压力绷带作为压力治疗为基础的伤口护理方案。
- VELVERT单用也可作为有效且耐受性好的选择。
- 治疗选择需结合伤口面积缩小、闭合率、微生物清除及安全性综合评估。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小,每组完成治疗例数有限(VELVERT组22例、VELVERT+VELSOFT组20例、VELFOUR组19例)。
- 随访至第60天或完全愈合,长期结局未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous leg ulcers (VLUs) are chronic, slow-healing wounds related to chronic venous insufficiency, and they represent a significant clinical and economic burden. Despite compression therapy being the standard of care, healing remains suboptimal in many patients, necessitating improved wound-care strategies. OBJECTIVE: To evaluate the comparative efficacy, safety, and clinical performance of VELVERT (Datt Mediproducts Private Limited) advanced wound-care dressing alone, VELVERT combined with VELSOFT (Datt Mediproducts Private Limited) compression bandage, and the VELFOUR (Datt Mediproducts Private Limited) four-layer compression system in the management of VLUs. METHODS: This randomized, interventional, open-label, multicentric clinical study was conducted at MLB Medical College, Jhansi, and Nizam Institute of Medical Sciences, Hyderabad. Sixty-six subjects were enrolled, of whom 61 completed treatments through day 60 or until complete wound healing. Primary end points included complete wound closure, percentage wound size reduction, and microbiological assessment. Secondary end points were pain intensity, safety, and the number of dressings required for healing. RESULTS: At day 60, mean wound size reduction was 57.72% in the VELVERT group (n = 22), 67.03% in the VELVERT + VELSOFT group (n = 20), and 65.79% in the VELFOUR group (n = 19). Overall, 42.6% of participants achieved complete wound closure, with the highest rate in the VELVERT + VELSOFT group (50.0%), followed by the VELFOUR (42.1%) and VELVERT (36.4%) groups. Complete microbial clearance occurred in the VELVERT and VELVERT + VELSOFT groups, whereas minimal residual microbial growth was observed in the VELFOUR group. Pain scores improved significantly across all groups. Adverse events were infrequent, mild to moderate, and unrelated to the study devices. CONCLUSIONS: All three treatment strategies improved wound healing, pain, and infection control. VELVERT combined with VELSOFT demonstrated the most consistent clinical benefits, including greater wound size reduction, the highest wound closure rate, complete microbial clearance, and an excellent safety profile. These findings support VELVERT with VELSOFT, and VELVERT alone, as effective and well-tolerated compression-based wound-care options for VLUs.
引用
- Mahapatra S, Anusha A, Athirath Reddy K, et al. Multicentric, randomized, open-label, three-arm postmarketing clinical study of VELVERT with single- and four-layer compression, for venous leg ulcer. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42732804. doi:10.1016/j.jvsv.2026.102621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。